Mylan's CEO defends soaring price of EpiPen

22 September 2016

The chief executive of Netherlands-incorporated Mylan (Nasdaq: MYL) has defended the company’s pricing strategy on its EpiPen allergy injection.

Since acquiring the product in late 2007, the company has increased the price by more than 500%, prompting a public outcry. The injector now costs more than $600 for a two-pen pack.

Appearing before the US Senate's House Committee on Oversight and Government Reform in Washington this week, Heather Bresch insisted the price tag was misleading. She said it did not take into account discounts and rebates negotiated with health insurers and added that, after costs had been deducted, Mylan received a profit of just $100 per pack.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK